The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
